​

4D Molecular Therapeutics (FDMT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

FDMT Stock Forecast

4D Molecular Therapeutics (FDMT) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 96.08% increase from the last price of $3.06.

- $7 $14 $21 $28 $35 High: $6 Avg: $6 Low: $6 Last Closed Price: $3.06

FDMT Stock Rating

4D Molecular Therapeutics stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (66.67%), 3 Hold (25.00%), 1 Sell (8.33%), and 0 Strong Sell (0.00%).

Buy
Total 12 0 1 3 8 Strong Sell Sell Hold Buy Strong Buy

FDMT Price Target Upside V Benchmarks

TypeNameUpside
Stock4D Molecular Therapeutics96.08%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$30.25
Last Closing Price$3.06$3.06$3.06
Upside/Downside--888.56%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 254521-12
Mar, 254521-12
Feb, 254521-12
Jan, 255521-13
Dec, 245511-12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 11, 2025Judah FrommerMorgan Stanley$6.00$5.528.70%96.08%
Sep 19, 2024Kostas BiliourisBMO Capital$40.00$13.28201.20%1207.19%
Sep 19, 2024Geulah LivshitsLoop Capital Markets$39.00$13.31193.01%1174.51%
Sep 19, 2024Matthew CaufieldH.C. Wainwright$36.00$13.31170.47%1076.47%
Apr 15, 2024Lisa WalterRBC Capital$40.00$26.3551.80%1207.19%
Apr 15, 2024Gena WangBarclays$45.00$26.3570.78%1370.59%
Apr 01, 2024Nalin TejavibulyaJefferies$58.00$31.8682.05%1795.42%
Mar 28, 2024Kostas BiliourisBMO Capital$63.00$31.5999.43%1958.82%
Feb 06, 2024Kostas BiliourisBMO Capital$70.00$30.71127.94%2187.58%
Jul 05, 2023Geulah LivshitsChardan Capital$30.00$18.4362.78%880.39%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 11, 2025Morgan StanleyUnderweightUnderweighthold
Jan 10, 2025BMO CapitalOutperformMarket Performdowngrade
Sep 23, 2024Cantor FitzgeraldNeutraldowngrade
Sep 19, 2024BMO CapitalOutperformOutperformhold
Sep 19, 2024Chardan CapitalBuyBuyhold
Sep 19, 2024H.C. WainwrightBuyBuyhold
Sep 09, 2024Chardan CapitalUnderperformUnderperformhold
Jul 22, 2024RBC CapitalOutperformOutperformhold
Jul 18, 2024RBC CapitalBuyBuyhold
Jun 07, 2024RBC CapitalBuyBuyhold

Financial Forecast

EPS Forecast

$-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.12$-2.46$-3.12$-2.58$-2.98----
Avg Forecast$-2.64$-2.78$-3.17$-2.61$-2.90$-3.56$-3.93$-3.87$-3.57
High Forecast$0.47$0.49$0.02$-2.25$-2.71$-3.26$-3.52$-3.38$0.03
Low Forecast$-7.17$-7.56$-6.90$-2.77$-3.00$-3.93$-4.26$-4.14$-7.75
Surprise %-19.70%-11.51%-1.58%-1.15%2.76%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$13.61M$18.04M$3.13M$20.72M-----
Avg Forecast$15.21M$18.83M$2.63M$22.61M$1.39M$3.76M$4.52M$35.27M$96.00M
High Forecast$35.32M$43.73M$5.01M$30.81M$4.51M$7.16M$8.61M$67.12M$182.70M
Low Forecast$1.44M$1.79M$593.09K$19.33M$32.82K$847.59K$1.02M$7.94M$21.62M
Surprise %-10.50%-4.21%18.82%-8.36%-----

Net Income Forecast

$-350M $-270M $-190M $-110M $-30M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-56.54M$-68.30M$-101.08M$-100.84M$-160.87M----
Avg Forecast$-103.17M$-108.88M$-124.15M$-100.84M$-111.73M$-140.69M$-152.39M$-147.06M$-139.56M
High Forecast$18.22M$19.23M$894.80K$-87.96M$-105.94M$-127.75M$-137.90M$-132.10M$1.01M
Low Forecast$-280.50M$-296.01M$-269.92M$-108.44M$-117.53M$-153.63M$-166.88M$-162.02M$-303.43M
Surprise %-45.20%-37.27%-18.59%-43.98%----

FDMT Forecast FAQ

Is 4D Molecular Therapeutics stock a buy?

4D Molecular Therapeutics stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that 4D Molecular Therapeutics is a favorable investment for most analysts.

What is 4D Molecular Therapeutics's price target?

4D Molecular Therapeutics's price target, set by 12 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 96.08% change from the previous closing price of $3.06.

How does 4D Molecular Therapeutics stock forecast compare to its benchmarks?

4D Molecular Therapeutics's stock forecast shows a 96.08% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for 4D Molecular Therapeutics over the past three months?

  • April 2025: 33.33% Strong Buy, 41.67% Buy, 16.67% Hold, 8.33% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 41.67% Buy, 16.67% Hold, 8.33% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 41.67% Buy, 16.67% Hold, 8.33% Sell, 0% Strong Sell.

What is 4D Molecular Therapeutics’s EPS forecast?

4D Molecular Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.56, marking a 19.46% increase from the reported $-2.98 in 2024. Estimates for the following years are $-3.93 in 2026, $-3.87 in 2027, and $-3.57 in 2028.

What is 4D Molecular Therapeutics’s revenue forecast?

4D Molecular Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $3.76M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $4.52M, followed by $35.27M for 2027, and $96M for 2028.

What is 4D Molecular Therapeutics’s net income forecast?

4D Molecular Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-141M, representing a -12.54% decrease from the reported $-161M in 2024. Projections indicate $-152M in 2026, $-147M in 2027, and $-140M in 2028.